MX2018002118A - Compuesto de tetrahidrooxepinopiridina. - Google Patents

Compuesto de tetrahidrooxepinopiridina.

Info

Publication number
MX2018002118A
MX2018002118A MX2018002118A MX2018002118A MX2018002118A MX 2018002118 A MX2018002118 A MX 2018002118A MX 2018002118 A MX2018002118 A MX 2018002118A MX 2018002118 A MX2018002118 A MX 2018002118A MX 2018002118 A MX2018002118 A MX 2018002118A
Authority
MX
Mexico
Prior art keywords
pam
effect
compound
receptor
tetrahydrooxepinopyridine
Prior art date
Application number
MX2018002118A
Other languages
English (en)
Inventor
Aoki Satoshi
Kawakami Shimpei
Kunikawa Shigeki
Koganemaru Yohei
Miyamoto Satoshi
Nagashima Shinya
Kamikawa Akio
Yonezawa Koichi
Koizumi Yuka
Ogiyama Takashi
Sato Ryo
Shishikura Junichi
Kakimoto Shuichirou
Yamada Hiroshi
Tamaki Keisuke
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2018002118A publication Critical patent/MX2018002118A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Problema. Se proporciona un compuesto que tiene una actividad moduladora alostérica positiva (actividad PAM) sobre un receptor de acetilcolina nicotínico a7 (receptor a7 nACh). Solución. Los presentes inventores han estudiado acerca de una actividad PAM sobre un receptor a7 nACh, y han confirmado que un compuesto de tetrahidrooxepinopiridina tiene una actividad PAM sobre un receptor a7 nACh, para completar la presente invención. El compuesto de tetrahidrooxepinopiridina de la presente invención tiene una actividad PAM sobre un receptor a7 nACh, y se puede esperar que sea útil como un agente para la prevención o el tratamiento de demencia, deterioro cognitivo, esquizofrenia, enfermedad de Alzheimer, CIAS, síntomas negativos de esquizofrenia, enfermedades inflamatorias o dolor.
MX2018002118A 2015-08-19 2016-08-18 Compuesto de tetrahidrooxepinopiridina. MX2018002118A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015162320 2015-08-19
PCT/JP2016/074145 WO2017030171A1 (ja) 2015-08-19 2016-08-18 テトラヒドロオキセピノピリジン化合物

Publications (1)

Publication Number Publication Date
MX2018002118A true MX2018002118A (es) 2018-06-18

Family

ID=58052257

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002118A MX2018002118A (es) 2015-08-19 2016-08-18 Compuesto de tetrahidrooxepinopiridina.

Country Status (21)

Country Link
US (1) US9670219B2 (es)
EP (1) EP3345909B1 (es)
JP (1) JP6787320B2 (es)
KR (1) KR102614279B1 (es)
CN (1) CN107922426B (es)
AR (1) AR105738A1 (es)
AU (1) AU2016308406A1 (es)
CA (1) CA2995554C (es)
CO (1) CO2018002472A2 (es)
EA (1) EA034794B1 (es)
ES (1) ES2812246T3 (es)
HK (1) HK1251574A1 (es)
IL (1) IL257450A (es)
MX (1) MX2018002118A (es)
PH (1) PH12018500297A1 (es)
PL (1) PL3345909T3 (es)
PT (1) PT3345909T (es)
SG (1) SG11201801193QA (es)
TW (1) TW201722962A (es)
WO (1) WO2017030171A1 (es)
ZA (1) ZA201801098B (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010020672A1 (en) * 2008-08-21 2010-02-25 Neurosearch A/S Novel phenyl-quinoline-carboxylic acid pyridine derivatives useful as modulators of nicotinic acetylcholine receptors
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
MY161236A (en) 2011-02-25 2017-04-14 Janssen Pharmaceutica Nv (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nachr
AR086791A1 (es) * 2011-07-01 2014-01-22 Lundbeck & Co As H Moduladores alostericos positivos del receptor de acetilcolina nicotinico
US20130005743A1 (en) * 2011-07-01 2013-01-03 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor

Also Published As

Publication number Publication date
BR112018003171A2 (pt) 2018-09-25
US9670219B2 (en) 2017-06-06
WO2017030171A1 (ja) 2017-02-23
KR20180037983A (ko) 2018-04-13
ZA201801098B (en) 2019-04-24
CO2018002472A2 (es) 2018-05-31
AR105738A1 (es) 2017-11-01
JPWO2017030171A1 (ja) 2018-06-07
KR102614279B1 (ko) 2023-12-18
EA034794B1 (ru) 2020-03-23
HK1251574A1 (zh) 2019-02-01
IL257450A (en) 2018-04-30
ES2812246T3 (es) 2021-03-16
US20170050973A1 (en) 2017-02-23
CA2995554A1 (en) 2017-02-23
EP3345909A1 (en) 2018-07-11
TW201722962A (zh) 2017-07-01
PT3345909T (pt) 2020-07-29
PH12018500297A1 (en) 2018-08-13
JP6787320B2 (ja) 2020-11-18
CN107922426B (zh) 2021-03-26
EA201890514A1 (ru) 2018-07-31
CA2995554C (en) 2023-06-27
CN107922426A (zh) 2018-04-17
EP3345909B1 (en) 2020-06-17
AU2016308406A1 (en) 2018-03-08
EP3345909A4 (en) 2019-04-10
PL3345909T3 (pl) 2020-10-19
SG11201801193QA (en) 2018-03-28

Similar Documents

Publication Publication Date Title
ZA201701299B (en) Glycosidase inhibitors
MX2018010192A (es) Inhibidores de glucosidasa.
MX2020002652A (es) Esteroides neuroactivos y su método de uso.
PH12018502028A1 (en) Allosteric modulators of nicotinic acetylcholine receptors
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
MX2018013472A (es) Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
MX2018010191A (es) Inhibidores de glucosidasa.
IN2015DN01156A (es)
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
TN2018000005A1 (en) Agents, uses and methods for the treatment of synucleinopathy
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
PH12018500268A1 (en) 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
PH12017501043A1 (en) 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
TW201613890A (en) Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
PH12019500196A1 (en) Compounds and compositions and uses thereof
MY174747A (en) Bace1 inhibitors
PH12019500198A1 (en) Compounds and compositions and uses thereof
PH12018500297A1 (en) Tetrahydrooxepinopyridine compound
MX2019002125A (es) Derivados de hidroxinorketamina para el tratamiento de trastornos.
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.
WO2015186144A3 (en) Method of inhibition of beta-secretase by using bis-o-demethylcurcumin for the prevention, management and treatment of neurodegenerative diseases

Legal Events

Date Code Title Description
FG Grant or registration